Clinical Trials Browser

Phase 2 × Has results × dacomitinib × Clear all

NCT01520870 2021-07-06

Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.

Phase 2 Completed

49 enrolled 9 charts

Brain Neoplasms, Glioblastoma, Recurrence

NCT00768664 2021-02-09

Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer

Phase 2 Completed

69 enrolled 18 charts

Head and Neck Neoplasms, Recurrence

NCT00548093 2019-05-21

PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib

Phase 2 Completed

66 enrolled 19 charts

Carcinoma, Non-Small-Cell Lung

NCT01465802 2019-01-09

ARCHER 1042

Phase 2 Completed

236 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung

NCT00818441 2019-01-08

Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung

Phase 2 Completed

119 enrolled 12 charts

Carcinoma

NCT01858389 2017-07-18

A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer

Phase 2 Completed

41 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT02047747 2016-09-22

A Phase II Study of Dacomitinib in Progressive Brain Metastases

Phase 2 Terminated

4 enrolled 4 charts

Brain Neoplasms, Neoplasm Metastasis

NCT00769067 2015-10-07

A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen

Phase 2 Completed

188 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis